Lumibird SA (FR:LBIRD)
:LBIRD
Want to see FR:LBIRD full AI Analyst Report?
Top Page
Lumibird SA
(LBIRD)
Select Model
Select Model
Rating:54Neutral
Price Target:
€22.00
▲(3.29% Upside)
Action:ReiteratedDate:04/29/26
The score is led by decent fundamental progress (especially improved 2025 profitability) but held back by cash-flow volatility and only modest earnings-to-free-cash-flow conversion. Technicals are soft with the stock below key short- and mid-term moving averages, and valuation looks demanding with a ~34 P/E and no dividend yield.
Positive Factors
Profitability improvement in 2025
A clear margin inflection in 2025 demonstrates the company can convert revenue into higher net profits, indicating operational improvements or a better mix toward higher-margin systems and services. Sustained higher margins would support reinvestment, debt service and resilience across cycles.
Negative Factors
Volatile free cash flow and modest cash conversion
Irregular FCF and low conversion from net income reduce internal funding for capex, R&D, and acquisitions and constrain ability to rapidly strengthen the balance sheet. Over months this increases reliance on external financing and raises risk if working-capital swings recur.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability improvement in 2025
A clear margin inflection in 2025 demonstrates the company can convert revenue into higher net profits, indicating operational improvements or a better mix toward higher-margin systems and services. Sustained higher margins would support reinvestment, debt service and resilience across cycles.
Read all positive factors
Lumibird SA (LBIRD) vs. iShares MSCI France ETF (EWQ)
Market Cap
€477.11M
Dividend YieldN/A
Average Volume (3M)32.82K
Price to Earnings (P/E)34.0
Beta (1Y)0.61
Revenue Growth8.93%
EPS Growth145.75%
CountryFR
Employees1,027
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.41
Shares Outstanding22,466,883
10 Day Avg. Volume22,637
30 Day Avg. Volume32,817
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.31
Price to Sales (P/S)2.08
P/FCF Ratio68.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.94
Revenue Forecast (FY)€247.93M
Lumibird SA Business Overview & Revenue Model
Company Description
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, high power laser...
How the Company Makes Money
Lumibird makes money primarily by selling photonics hardware and associated systems, with revenue typically recognized through product shipments and customer acceptance. Key revenue streams include: (1) Laser sources and components: sales of laser...
Lumibird SA Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
61
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 228.53M | 210.06M | 206.55M | 194.29M | 162.47M |
| Gross Profit | 146.24M | 16.06M | 128.11M | 15.36M | 18.49M |
| EBITDA | 44.32M | 31.03M | 27.31M | 32.09M | 31.81M |
| Net Income | 14.00M | 5.70M | 7.13M | 11.35M | 13.86M |
Balance Sheet | |||||
| Total Assets | 428.90M | 429.80M | 405.25M | 372.04M | 347.62M |
| Cash, Cash Equivalents and Short-Term Investments | 61.60M | 71.14M | 56.20M | 61.68M | 97.13M |
| Total Debt | 146.20M | 161.06M | 145.08M | 114.18M | 112.03M |
| Total Liabilities | 222.60M | 231.79M | 211.95M | 178.61M | 166.29M |
| Stockholders Equity | 206.30M | 198.01M | 193.30M | 193.44M | 181.33M |
Cash Flow | |||||
| Free Cash Flow | 7.00M | 11.41M | -4.89M | -28.02M | 6.47M |
| Operating Cash Flow | 23.10M | 34.37M | 20.67M | 1.43M | 26.57M |
| Investing Cash Flow | -15.90M | -22.84M | -46.15M | -29.34M | -28.63M |
| Financing Cash Flow | -10.70M | 3.39M | 21.69M | -7.89M | 18.20M |
Lumibird SA Technical Analysis
Positive
21.30
Price Trends
22.32
Positive
21.88
Positive
20.61
Positive
Market Momentum
0.22
Negative
60.82
Neutral
82.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:LBIRD, the sentiment is Positive. The current price of 21.3 is below the 20-day moving average (MA) of 21.76, below the 50-day MA of 22.32, and above the 200-day MA of 20.61, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 60.82 is Neutral, neither overbought nor oversold. The STOCH value of 82.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:LBIRD.
Lumibird SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | €8.47B | 32.73 | 9.69% | 0.82% | 2.26% | -8.10% | |
56 Neutral | €15.25B | 45.89 | 6.65% | 0.31% | 4.43% | 31.23% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €477.11M | 34.02 | 5.51% | ― | 8.93% | 145.75% | |
48 Neutral | €181.92M | -5.11 | 59.08% | ― | 1.79% | 15.89% | |
46 Neutral | €35.35M | 1.19 | ― | ― | 7.43% | ― | |
46 Neutral | €29.09M | -6.16 | 467.60% | ― | 42.86% | 13.93% |
* General Sector Average
FR:LBIRD
Lumibird SA
21.50
10.20
90.27%
FR:BIM
bioMerieux
71.70
-46.12
-39.15%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.18
0.09
93.68%
FR:DIM
Sartorius Stedim Biotech
156.70
-48.66
-23.70%
FR:ALTHE
Theraclion SA
0.48
0.25
108.70%
FR:ALMDT
Median Technologies
4.84
2.43
101.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.